Page last updated: 2024-09-04

docetaxel anhydrous and Metabolic Syndrome

docetaxel anhydrous has been researched along with Metabolic Syndrome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ali Sanli, U; Bicakli, DH; Cakar, B; Degirmenci, M; Durusoy, R; Karaca, B; Tunali, D; Uslu, R; Varol, U	1

Other Studies

1 other study(ies) available for docetaxel anhydrous and Metabolic Syndrome

Article	Year
Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Metabolic Syndrome; Middle Aged; Risk; Taxoids; Treatment Outcome	2016

Article

Year

Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:1

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Metabolic Syndrome; Middle Aged; Risk; Taxoids; Treatment Outcome

2016